Total Payments
$171,414
2024 Payments
$1,639
Companies
37
Transactions
701
Medicare Patients
1,015
Medicare Billing
$260,268
Payment Breakdown by Category
Other$91,857 (53.6%)
Consulting$52,484 (30.6%)
Travel$12,953 (7.6%)
Food & Beverage$11,724 (6.8%)
Research$1,966 (1.1%)
Education$429.82 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $89,882 | 46 | 52.4% |
| Consulting Fee | $52,484 | 24 | 30.6% |
| Travel and Lodging | $12,953 | 78 | 7.6% |
| Food and Beverage | $11,724 | 543 | 6.8% |
| Honoraria | $1,975 | 1 | 1.2% |
| Unspecified | $1,966 | 1 | 1.1% |
| Education | $429.82 | 8 | 0.3% |
Payments by Type
General
$169,448
700 transactions
Research
$1,966
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $86,871 | 137 | $0 (2024) |
| Amgen Inc. | $37,279 | 120 | $0 (2024) |
| ABBVIE INC. | $18,617 | 72 | $0 (2024) |
| GlaxoSmithKline, LLC. | $7,155 | 61 | $0 (2024) |
| UCB, Inc. | $7,019 | 25 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $5,658 | 15 | $0 (2024) |
| Celgene Corporation | $2,268 | 20 | $0 (2019) |
| Horizon Therapeutics plc | $2,065 | 7 | $0 (2023) |
| Janssen Biotech, Inc. | $904.41 | 36 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $841.84 | 43 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,639 | 79 | Novartis Pharmaceuticals Corporation ($449.12) |
| 2023 | $11,120 | 79 | UCB, Inc. ($5,966) |
| 2022 | $2,619 | 39 | E.R. Squibb & Sons, L.L.C. ($1,444) |
| 2021 | $8,917 | 18 | E.R. Squibb & Sons, L.L.C. ($8,813) |
| 2020 | $25,165 | 45 | E.R. Squibb & Sons, L.L.C. ($16,530) |
| 2019 | $27,239 | 138 | E.R. Squibb & Sons, L.L.C. ($16,566) |
| 2018 | $32,714 | 143 | E.R. Squibb & Sons, L.L.C. ($14,862) |
| 2017 | $62,001 | 160 | Amgen Inc. ($27,726) |
All Payment Transactions
701 individual payment records from CMS Open Payments — Page 1 of 29
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $15.50 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/11/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $17.47 | General |
| Category: Immunology | ||||||
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $22.43 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $20.97 | General |
| Category: Immunology | ||||||
| 12/02/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $29.83 | General |
| Category: Dermatology | ||||||
| 12/02/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $27.34 | General |
| Category: Dermatology | ||||||
| 11/21/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $14.22 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $13.44 | General |
| Category: IMMUNOLOGY | ||||||
| 11/17/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $36.83 | General |
| Category: Immunology | ||||||
| 11/16/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $134.94 | General |
| 11/14/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $28.59 | General |
| Category: Immunology | ||||||
| 11/07/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $17.09 | General |
| 11/05/2024 | Radius Health, Inc. | Tymlos (Drug) | Food and Beverage | In-kind items and services | $23.33 | General |
| Category: Endocrinology | ||||||
| 10/30/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $18.06 | General |
| Category: IMMUNOLOGY | ||||||
| 10/24/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $18.66 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/22/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $18.17 | General |
| Category: Immunology | ||||||
| 10/17/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $15.15 | General |
| Category: IMMUNOLOGY | ||||||
| 10/14/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $24.85 | General |
| Category: Dermatology | ||||||
| 10/14/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $8.62 | General |
| Category: IMMUNOLOGY | ||||||
| 10/03/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Education | In-kind items and services | $99.00 | General |
| Category: Immunology | ||||||
| 09/25/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $25.13 | General |
| Category: Dermatology | ||||||
| 09/24/2024 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $16.23 | General |
| Category: Immunology | ||||||
| 09/20/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $13.77 | General |
| Category: IMMUNOLOGY | ||||||
| 09/17/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $16.31 | General |
| Category: Dermatology | ||||||
| 09/12/2024 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $18.19 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CC-10004-BCT-002 - A phase 3, multicenter, randomized, doubleblind, placebo-controlled, parallel group study, followed by an active-treatment phase to evaluate the efficacy and safety of apremilast (CC-10004) in the tre | Celgene Corporation | $1,966 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 165 | 2,397 | $168,920 | $66,575 |
| 2022 | 5 | 216 | 2,157 | $166,054 | $60,808 |
| 2021 | 5 | 309 | 3,177 | $230,705 | $86,081 |
| 2020 | 6 | 325 | 1,246 | $161,953 | $46,804 |
Total Patients
1,015
Total Services
8,977
Medicare Billing
$260,268
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 21 | 2,040 | $67,320 | $37,700 | 56.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 78 | 151 | $54,813 | $15,773 | 28.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 38 | 77 | $37,499 | $11,552 | 30.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 28 | 129 | $9,288 | $1,550 | 16.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 21 | 1,740 | $54,840 | $29,940 | 54.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 106 | 200 | $72,600 | $20,605 | 28.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 28 | 36 | $17,532 | $5,443 | 31.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 37 | 46 | $11,362 | $3,168 | 27.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 24 | 135 | $9,720 | $1,651 | 17.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 25 | 2,580 | $76,560 | $42,224 | 55.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 146 | 281 | $102,003 | $29,485 | 28.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 92 | 130 | $32,110 | $9,694 | 30.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 14 | 16 | $7,792 | $2,556 | 32.8% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 32 | 170 | $12,240 | $2,123 | 17.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 150 | 264 | $95,832 | $21,939 | 22.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2020 | 12 | 780 | $21,300 | $12,460 | 58.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 97 | 121 | $29,801 | $7,446 | 25.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 17 | 20 | $9,722 | $2,527 | 26.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 32 | 32 | $3,210 | $2,050 | 63.9% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2020 | 17 | 29 | $2,088 | $382.22 | 18.3% |
About Dr. Elliot Rosenstein, M.D
Dr. Elliot Rosenstein, M.D is a Rheumatology healthcare provider based in Summit, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1174585145.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Elliot Rosenstein, M.D has received a total of $171,414 in payments from pharmaceutical and medical device companies, with $1,639 received in 2024. These payments were reported across 701 transactions from 37 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($89,882).
As a Medicare-enrolled provider, Rosenstein has provided services to 1,015 Medicare beneficiaries, totaling 8,977 services with total Medicare billing of $260,268. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Summit, NJ
- Active Since 04/05/2006
- Last Updated 02/09/2016
- Taxonomy Code 207RR0500X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1174585145
Products in Payments
- ORENCIA (Biological) $27,475
- Enbrel (Biological) $17,509
- Rinvoq (Biological) $4,899
- RINVOQ (Drug) $4,028
- Bimzelx (Biological) $3,033
- Humira (Biological) $2,195
- KRYSTEXXA (Biological) $2,067
- Otezla (Drug) $1,985
- BENLYSTA (Biological) $880.37
- OFEV (Drug) $820.19
- TREMFYA (Drug) $618.22
- XELJANZ (Drug) $597.98
- COSENTYX (Drug) $502.81
- Cimzia (Drug) $360.06
- Rituxan (Biological) $330.69
- RINVOQ (Biological) $231.65
- TALTZ (Drug) $176.26
- COSENTYX (Biological) $170.26
- Actemra (Biological) $160.22
- REMICADE (Biological) $138.85
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Summit
Dr. Jeffrey Greenberg, Md, MD
Rheumatology — Payments: $469,155
Rheumatology $469,155
Neil Kramer, Md, MD
Rheumatology — Payments: $41,154
Rheumatology $41,154
Krissy Choi, Do, DO
Rheumatology — Payments: $9,475
Rheumatology $9,475
Katherine Ruddy, Md, MD
Rheumatology — Payments: $208.55
Rheumatology $208.55